Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Licensing deals
Biotech
Novo Nordisk signs $530M biobucks deal to sing in Korro's opera
Novo isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro on two cardiometabolic-related targets.
James Waldron
Sep 16, 2024 9:40am
Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail
Sep 12, 2024 9:30am
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Sep 10, 2024 7:57am
Novartis ignites new stage of Voyager pact with $15M capsid deal
Sep 5, 2024 9:45am
Bayer pens $547M pact to push boundaries of noncoding RNA
Aug 28, 2024 9:00am
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
